David S. Joseph
Mr. Joseph is a Co-Founder of Avisa Pharma with forty years of healthcare and life science management; co-founder and CEO of five companies in medical technology, biomaterials and biopharmaceuticals. Mr. Joseph served as Chairman and CEO of Othera Pharmaceuticals and co-founder and of Orthovita Inc, a company he also where he also served as President and CEO. Stryker Corporation acquired Orthovita in 2012. Prior to Orthovita, Mr. Joseph co-founded two medical device companies: Surgical Laser Technologies, Inc., which became public in 1989 and SITE Microsurgical Systems, which was acquired by Johnson & Johnson Corporation in 1983. He also has over 15 years of executive healthcare management experience. Mr. Joseph received the Greater Philadelphia Venture Group’s Raymond Rafferty Entrepreneurial Excellence Award in May 2005 for having founded four successful venture-backed companies and for his influence on the ophthalmic and medical technology industries.
His past and present board appointments include Animas Corporation, a diabetes insulin pump technology acquired by Johnson & Johnson in 2006; Aspire Bariatics Inc., an obesity technology company; Seamless Medical Systems, a patient engagement and media company. HTH Worldwide, a privately held internet travel health insurance and information company; Morphotek Inc., a privately held biotechnology company acquired by Eisai Pharmaceuticals in 2007; TLC Vision, a leader in Lasik surgery centers; Managed Healthcare Services, Inc.; The Jackson Laboratory Board of Governing Trustees; and King’s College Board of Directors.
Mr. Bedwick is the Director of a Hong Kong-based asset management company with a specialty in Pan Asian financial markets. He has spent the past 25 years in Asia running proprietary trading desks for Greenwich NatWest Securities, Deutsche Bank and Lehman Brothers; from 2009, he acted as Portfolio Manager of Sequence Fundamental Macro Fund (that he founded) and also as CIO of Sequence Asset Management, a Hong Kong based and SFC registered asset management firm. He is a very experienced private equity investor with particular focus in early stage life science companies and has sat on the board of a number of those companies. Mr. Bedwick received his BS in Biology/Pre-Medical Studies from the University of Scranton and attended Thomas Jefferson Medical College in Philadelphia.
Brian Birk has over 20 years experience as an operating executive and investor. Mr. Birk co-founded Sun Mountain Capital in 2006, a boutique private equity firm focused on the Southwest and Rocky Mountain regions. Since that time Sun Mountain has grown to be one of the largest PE firms in the region, and currently manages direct investment funds and fund of funds vehicles. Prior to forming Sun Mountain Capital, Mr. Birk was a Vice President and Director of Private Equity at Fort Washington Capital Partners where he helped the firm establish and manage a number of private equity direct investment funds, secondary investment funds, and fund of funds programs.
William A. Miller
Mr. Miller is President of Miller Strategic Consulting, LLC, a consulting practice that invests in and actively participates in the management and development of start-up companies. He has co-founded some fifteen start-up companies, including Technicare Corporation where he served as Executive VP, CFO and Board Member, as well as Hitatchi Medical Systems of America where he was both on the Board of Directors and the Executive Steering Committee. He is currently a member of the board of InLight Solutions and Lumidigm Inc. in addition to SITE Santa Fe, Wasatch New Mexico Fund, Avalon Trust Company and the Santa Fe Art Institute. Mr. Miller received a BA in Philosophy from Ohio Wesleyan University and an MBA in Finance from the Booth School of Business at the University of Chicago, where he also serves on the school’s Entrepreneurial Advisory Board.
J. Chuck Morrison
Chuck is a Global Business Development Executive with a successful track record negotiating and executing acquisitions, licensing deals, partnerships, and distribution deals. Chuck has 40 years of experience in Life Science, Biotechnology and Diagnostics, including 20 years of Corporate Business Development and 20 years of Operations Management.
While at PerkinElmer Chuck managed numerous acquisitions and technology deals which drove the strategic growth of PerkinElmer’s Life Science and Diagnostic businesses. As a senior member of the Diagnostic leadership team, that business grew from $70M to $400M in 7 years.
Chuck has continued his career as an independent consultant, providing business development and management experience to small biotech companies. Chuck is also a Board member for GenePOC Inc., a privately owned company (part of the Debiopharm Group), that has developed a molecular diagnostic platform. Board duties include being active member of the Strategic Committee and the Audit Committee.
MBA, Finance and Marketing, Boston University, Boston, MA
BA, Chemistry, College of the Holy Cross, Worcester, MA
Thomas R. Morse
Mr. Morse is a Managing Partner of Liberty Venture Partners, which he founded in 1996 following several years as a partner at Philadelphia Ventures. He brings a proven track record of successfully managing the growth of early stage medical technology and healthcare IT companies. Mr. Morse has acted as a director of numerous portfolio companies, including Animas, Nellcor, Acoustic Imaging Technologies Corporation, Ultracision, Coalescent Surgical, Adhezion BioMedical, Xanitos, and MEDecision. He received his BS in Mechanical Engineering from the United States Naval Academy and then served as a nuclear submarine officer before earning an MBA in finance from the Wharton School at the University of Pennsylvania. Mr. Morse is a CFA charter holder.
Mr. Schoenmann brings more than 25 years of expertise in the applied technology and high-tech manufacturing industry to the Avisa Board of Directors with 12 years of CEO or COO experience. Currently, an Operating Partner at Norwest Equity Partners, he helps evaluate and execute new investment opportunities and add-on acquisitions within the applied technology industry sector. He also plays an active role in strategic planning, business growth and corporate governance for Norwest Equity Partners portfolio companies. Mr. Schoenmann previously served as CEO of CVI Melles Griot, a leading global designer and manufacturer of precision photonics products. During his tenure, he built CVI into a leader within the photonics industry, transitioning the company into a diversified photonics supplier, aggressively expanding its product offerings, and completing four add-on acquisitions before overseeing the sale of the company to IDEX Corporation in 2011. He has also held leadership roles at several top applied technology companies, including Raytek, Corning, PerkinElmer and Rockwell International. Mr. Schoenmann received a BA in Physics from the University of California San Diego and an MBA from the University of Southern California.